Tekmira Pharmaceuticals Corporation  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
18.97
0.00 (0.00%)
Oct 30 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 7.61 - 34.66
Open     -
Vol / Avg. 0.00/306,015.00
Mkt cap 418.95M
P/E     -
Div/yield     -
EPS -1.93
Shares 22.08M
Beta 0.28
Inst. own     -
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Call - 5:00PM EST - Add to calendar
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Release - 4:00PM EST - Add to calendar
Oct 7, 2014
Tekmira Pharmaceuticals Corp at BIO Investor Forum
Oct 1, 2014
Tekmira Pharmaceuticals Corp at Leerink Rare Disease Roundtable
Sep 22, 2014
Tekmira Pharmaceuticals Corp at Maxim Group's Institutional NYC BioDefense Mini-Conference
Aug 13, 2014
Q2 2014 Tekmira Pharmaceuticals Corp Earnings Call
Aug 13, 2014
Q2 2014 Tekmira Pharmaceuticals Corp Earnings Release
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -335.78% -90.95%
Operating margin -520.32% -78.59%
EBITD margin - -74.63%
Return on average assets -18.03% -22.63%
Return on average equity -23.16% -28.10%
Employees 85 -
CDP Score - -

Address

Suite 100, 8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 67
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Age: 50
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
R. Hector MacKay-Dunn QC Corporate Secretary
Peggy V. Phillips Director
Age: 60
Donald G. Jewell Independent Director
Age: 60